Øystein Brenna (f. 1975) er ph.d., spesialist i indremedisin og i fordøyelsessykdommer og overlege.
Forfatter har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter.
()
1.
Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010; 56: 1 - 7. [PubMed][CrossRef]
2.
Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis - current understanding from an epidemiological point of view. Br J Haematol 2010; 149: 824 - 33. [PubMed][CrossRef]
3.
Landolfi R, Marchioli R, Patrono C. Mechanisms of bleeding and thrombosis in myeloproliferative disorders. Thromb Haemost 1997; 78: 617 - 21. [PubMed]
4.
Kahn SR, Galanaud JP, Vedantham S et al. Guidance for the prevention and treatment of the post-thrombotic syndrome. J Thromb Thrombolysis 2016; 41: 144 - 53. [PubMed][CrossRef]
5.
Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355: 2452 - 66. [PubMed][CrossRef]
6.
Faderl S, Talpaz M, Estrov Z et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164 - 72. [PubMed][CrossRef]
Imazio M, Gaita F. Diagnosis and treatment of pericarditis. Heart 2015; 101: 1159 - 68. [PubMed][CrossRef]
9.
Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet 2006; 367: 241 - 51. [PubMed][CrossRef]
10.
Cronin CG, Lohan DG, Blake MA et al. Retroperitoneal fibrosis: a review of clinical features and imaging findings. AJR Am J Roentgenol 2008; 191: 423 - 31. [PubMed][CrossRef]
11.
Urban ML, Palmisano A, Nicastro M et al. Idiopathic and secondary forms of retroperitoneal fibrosis: a diagnostic approach. Rev Med Interne 2015; 36: 15 - 21. [PubMed][CrossRef]
12.
Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993; 81: 1607 - 13. [PubMed]
13.
Gogolak P, Rethi B, Szatmari I et al. Differentiation of CD1a- and CD1a+ monocyte-derived dendritic cells is biased by lipid environment and PPARgamma. Blood 2007; 109: 643 - 52. [PubMed][CrossRef]
14.
Wheeler LC, Donor MT, Prell JS et al. Multiple Evolutionary Origins of Ubiquitous Cu2+ and Zn2+ Binding in the S100 Protein Family. PLoS One 2016; 11: e0164740. [PubMed][CrossRef]
15.
Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949 - 54. [PubMed][CrossRef]
16.
Haroche J, Charlotte F, Arnaud L et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 120: 2700 - 3. [PubMed][CrossRef]
17.
Cangi MG, Biavasco R, Cavalli G et al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis 2015; 74: 1596 - 602. [PubMed][CrossRef]
18.
Emile JF, Diamond EL, Hélias-Rodzewicz Z et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 2014; 124: 3016 - 9. [PubMed][CrossRef]
19.
Haroche J, Cohen-Aubart F, Charlotte F et al. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. Expert Rev Clin Immunol 2015; 11: 1033 - 42. [PubMed][CrossRef]
20.
Stoppacciaro A, Ferrarini M, Salmaggi C et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 2006; 54: 4018 - 22. [PubMed][CrossRef]
21.
Arnaud L, Gorochov G, Charlotte F et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011; 117: 2783 - 90. [PubMed][CrossRef]
22.
Cavalli G, Biavasco R, Borgiani B et al. Oncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease. Front Immunol 2014; 5: 281. [PubMed][CrossRef]
23.
Emile JF, Abla O, Fraitag S et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016; 127: 2672 - 81. [PubMed][CrossRef]
24.
Campochiaro C, Tomelleri A, Cavalli G et al. Erdheim-Chester disease. Eur J Intern Med 2015; 26: 223 - 9. [PubMed][CrossRef]
25.
Haroche J, Arnaud L, Cohen-Aubart F et al. Erdheim-Chester disease. Rheum Dis Clin North Am 2013; 39: 299 - 311. [PubMed][CrossRef]
26.
Midtvedt Ø, Gran JT, Solheim H et al. En mann i 40-årene med hevelse i begge øyehuler. Tidsskr Nor Legeforen 2014; 134: 1472 - 6. [PubMed][CrossRef]
27.
Diamond EL, Dagna L, Hyman DM et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 2014; 124: 483 - 92. [PubMed][CrossRef]
28.
Cives M, Simone V, Rizzo FM et al. Erdheim-Chester disease: a systematic review. Crit Rev Oncol Hematol 2015; 95: 1 - 11. [PubMed][CrossRef]
29.
Antunes C, Graça B, Donato P. Thoracic, abdominal and musculoskeletal involvement in Erdheim-Chester disease: CT, MR and PET imaging findings. Insights Imaging 2014; 5: 473 - 82. [PubMed][CrossRef]
Denne artikkelen ble publisert for mer enn 12 måneder siden, og vi har derfor stengt for nye kommentarer.
Publisert: 6. juni 2018
Utgave 10, 12. juni 2018
Tidsskr Nor Legeforen 6. juni 2018
doi:
10.4045/tidsskr.17.0817
Mottatt 4.10.2018, første revisjon innsendt 11.3.2018, godkjent 15.3.2018.
Får du ikke vist PDF-filen eller vil lagre filen, kan du høyreklikke på PDF-ikonet. Velg «Lagre mål/fil som..» og hent så opp PDF-filen i for eksempel Acrobat Reader.